Role of key point Mutations in Receptor Binding Domain of SARS-CoV-2 Spike Glycoprotein.

Infect Disord Drug Targets

Department of Applied Sciences, BML Munjal University, Sidhrawali, Gurugram-122413, Haryana, India.

Published: October 2021


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

The recent outbreak of novel coronavirus (SARS-CoV-2 or 2019-nCoV) and its worldwide spread is posing one of the major threats to human health and the world economy. It has been suggested that SARS-CoV-2 is similar to SARS-CoV based on the comparison of the genome sequence. Despite the genomic similarity between SARS-CoV-2 and SARS-CoV, the spike glycoprotein and receptor binding domain in SARS-CoV-2 shows the considerable difference compared to SARS-CoV, due to the presence of several point mutations. The analysis of receptor binding domain (RBD) from recently published 3D structures of spike glycoprotein of SARS-CoV-2 (Yan, R., et al. (2020); Wrapp, D., et al. (2020); Walls, A. C., et al. (2020)) highlights the contribution of a few key point mutations in RBD of spike glycoprotein and molecular basis of its efficient binding with human angiotensin-converting enzyme 2 (ACE2).

Download full-text PDF

Source
http://dx.doi.org/10.2174/1871526520666200804161650DOI Listing

Publication Analysis

Top Keywords

spike glycoprotein
16
point mutations
12
receptor binding
12
binding domain
12
key point
8
domain sars-cov-2
8
sars-cov-2 sars-cov
8
sars-cov-2
6
role key
4
mutations receptor
4

Similar Publications

Introduction: The COVID-19 pandemic had significant global public health consequences, affecting over 200 countries and regions by 2020. The development and efficacy of specific vaccines, such as the mRNA-1273 (Spikevax) vaccine developed by Moderna Inc., have substantially reduced the impact of the pandemic and mitigated its consequences.

View Article and Find Full Text PDF

Vaccines of enhanced range of protection could help to control newly emerging infectious diseases while providing greater resilience to any subsequent variants. Such "universal vaccines" are an idealized, but unrealized, goal that may benefit from unbiased, high-throughput approaches that define antibody cross-reactivity to enable rational selection of cross-protective epitopes. The priority of this investigation is to establish a pipeline for the identification and preliminary characterization of epitopes with enhanced cross-reactivity.

View Article and Find Full Text PDF

The exact details of the emergence of SARS-CoV-2, the virus causing Covid-19, remain unknown. Scientific publications using data available to date point to a natural origin linked to the wildlife trade at a market in Wuhan, China. Yet, theories postulating a research-related origin of SARS-CoV-2 abound, and currently dominate the public discussion of the origin of the Covid-19 pandemic.

View Article and Find Full Text PDF

The XBB.1.5 COVID-19 vaccine elicits a durable antibody response to ancestral and XBB.1.5 SARS-CoV-2 spike proteins.

Sci Transl Med

September 2025

Center for Childhood Infections and Vaccines, Children's Healthcare of Atlanta, Division of Infectious Diseases, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA 30322, USA.

The rapid emergence of divergent SARS-CoV-2 variants led to a 2023-2024 update of the COVID-19 mRNA vaccine to a monovalent version containing the XBB.1.5 SARS-CoV-2 spike antigen.

View Article and Find Full Text PDF

SARS-CoV-2 antibody and neutralization dynamics among persons with natural- and vaccine-induced exposures.

PLoS One

September 2025

Agencia Costarricense de Investigaciones Biomédicas-Fundación INCIENSA (ACIB-FUNIN), San José, Costa Rica.

Previous SARS-CoV-2 research indicates that antibody levels and corresponding neutralization potential increase with additional exposures (comprising vaccination or infection), and that hybrid immunity resulting from combined vaccination and natural infection is more robust than either alone. However, it is unclear whether or how antibody levels increase or eventually plateau with repeated exposures and how SARS-CoV-2 exposure differs by sex or other demographic factors. Research regarding the association of antibody production with neutralization potential is also limited.

View Article and Find Full Text PDF